Response Genetics, Inc.
RGDX, a company focused on the development and sale of molecular
diagnostic tests that help guide cancer therapy selection, today announced the
availability of new testing capabilities to advance cancer immunotherapy
clinical development. The Immuno-Oncology assay, which runs on HTG Molecular's
Edge System, is designed to measure the RNA expression of 26 commonly
investigated immunotherapy related genes enabling screening for response to
immunoregulatory pathways. The Iummo-Oncology test will be made available to
all of Response Genetics' existing biopharmaceutical partners, and new
potential partners, to aid in development of biomarker driven cancer
immunotherapy clinical trials.
"As the field of cancer immunotherapy continues to expand with potential
immunotherapeutic targets in a broad range of malignancies, we are pleased to
add immunotherapy testing to the portfolio of services we offer to our
biopharma clients," said Thomas A. Bologna, Chairman and Chief Executive
Officer of Response Genetics. "Regulation of the immune system is the key to
several therapeutic approaches for cancer treatment. A number of clinical
development programs being pioneered by large pharma are focused on signaling
pathways like PD-1, PD-L1, OX-40, LAG3 and CTLA4 with the goal of enabling the
immune system to attack cancer cells. The new assay covers these pathways as
well as numerous other targets."
Mr. Bologna added, "As evidenced at the recent annual meeting of the American
Society of Clinical Oncology, the characterization of biomarkers of response
to immunotherapeutic agents is focused on the expression levels of the
relevant receptors and ligands. Response Genetics was among the first
commercial organizations to harness the power of mRNA expression profiling as
a means to guide cancer therapy selection. The addition of the Immuno-Oncology
assay allows our pharma partners to further leverage our expertise in
RNA-based testing to shed light on potential biomarkers that identify patients
likely to respond to this new class of therapies."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in